Skip to content
Lipid metabolism as targetable weakness of prostate cancer

Publications

2024

  1. Ola, IO, Talala, K, Tammela, T, Taari, K, Murtola, TJ, Kujala, P et al.. Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Oncol. 2024; :. doi: 10.1016/j.euo.2024.11.010. PubMed PMID:39643505 .
  2. Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
  3. Murtola, TJ, Siltari, A, Raittinen, P, Tammela, TLJ, Linder, S, Csizmarik, A et al.. Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer. Eur Urol Open Sci. 2024;70 :135-141. doi: 10.1016/j.euros.2024.10.010. PubMed PMID:39525979 PubMed Central PMC11547961.
  4. Lawlor, A, Beyer, K, Russell, B, Steinbeisser, C, Bjartell, A, De Meulder, B et al.. PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. Nat Rev Urol. 2024; :. doi: 10.1038/s41585-024-00925-4. PubMed PMID:39251785 .
  5. Ahtinen, M, Vironen, J, Murtola, TJ. Previous inguinal hernia surgery does not limit the likelihood of choosing prostatectomy as primary prostate cancer therapy. Sci Rep. 2024;14 (1):9943. doi: 10.1038/s41598-024-60451-6. PubMed PMID:38688937 PubMed Central PMC11061137.
  6. Jussila, I, Ahtiainen, JP, Laakkonen, EK, Siltari, A, Kaipia, A, Jokela, T et al.. Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol. BJU Int. 2024;134 (1):110-118. doi: 10.1111/bju.16361. PubMed PMID:38587276 .
  7. Auvinen, A, Tammela, TLJ, Mirtti, T, Lilja, H, Tolonen, T, Kenttämies, A et al.. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024;331 (17):1452-1459. doi: 10.1001/jama.2024.3841. PubMed PMID:38581254 PubMed Central PMC10999002.
  8. Wang, Y, Chen, J, Gong, L, Wang, Y, Siltari, A, Lou, YR et al.. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC. J Nanobiotechnology. 2024;22 (1):145. doi: 10.1186/s12951-024-02438-z. PubMed PMID:38566211 PubMed Central PMC10985917.
  9. Pajunen, H, Veitonmäki, T, Huhtala, H, Nikkola, J, Pöyhönen, A, Murtola, T et al.. Prognostic factors of renal cell cancer in elderly patients: a population-based cohort study. Sci Rep. 2024;14 (1):6295. doi: 10.1038/s41598-024-56835-3. PubMed PMID:38491173 PubMed Central PMC10942969.
  10. Löffeler, S, Bertilsson, H, Müller, C, Aas, K, Haugnes, HS, Aksnessæther, B et al.. Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). BJU Int. 2024;133 (6):680-689. doi: 10.1111/bju.16314. PubMed PMID:38469686 .
  11. Russell, B, Beyer, K, Lawlor, A, Roobol, MJ, Venderbos, LDF, Remmers, S et al.. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?. Eur Urol Open Sci. 2024;59 :27-29. doi: 10.1016/j.euros.2023.11.004. PubMed PMID:38298764 PubMed Central PMC10829596.
  12. Nolsøe, AB, Holm, HV, Murtola, TJ, Østergren, PB, Fode, M. Management of functional outcomes after radical prostatectomy in the Nordic countries: A survey of uro-oncological centers. Int J Impot Res. 2024;36 (5):486-492. doi: 10.1038/s41443-023-00772-8. PubMed PMID:37816870 PubMed Central PMC11251983.
  13. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2024;27 (1):73-80. doi: 10.1038/s41391-022-00597-4. PubMed PMID:36131010 PubMed Central PMC10876474.

Search PubMed

2023
  1. Murto, MO, Simolin, N, Arponen, O, Siltari, A, Artama, M, Visvanathan, K et al.. Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer. JAMA Netw Open. 2023;6 (11):e2343861. doi: 10.1001/jamanetworkopen.2023.43861. PubMed PMID:37976058 PubMed Central PMC10656638.
  2. Siltari, A, Murtola, TJ, Kausz, J, Talala, K, Taari, K, Tammela, TL et al.. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men. Acta Oncol. 2023;62 (12):1898-1904. doi: 10.1080/0284186X.2023.2278189. PubMed PMID:37971326 .
  3. Peltomaa, AI, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Statin use and outcomes of oncological treatment for castration-resistant prostate cancer. Sci Rep. 2023;13 (1):18866. doi: 10.1038/s41598-023-45958-8. PubMed PMID:37914793 PubMed Central PMC10620176.
  4. Nolsøe, AB, Holm, HV, Murtola, TJ, Østergren, PB, Fode, M. Management of functional outcomes after radical prostatectomy in the Nordic countries: A survey of uro-oncological centers. Int J Impot Res. 2024;36 (5):486-492. doi: 10.1038/s41443-023-00772-8. PubMed PMID:37816870 PubMed Central PMC11251983.
  5. Haapiainen, H, Murtola, TJ, Koskimäki, J, Riikonen, J, Pakarainen, T, Haney, CM et al.. Robot-assisted versus three-dimensional laparoscopic radical prostatectomy: 12-month outcomes of a randomised controlled trial. BJU Int. 2023;132 (5):505-511. doi: 10.1111/bju.16132. PubMed PMID:37461186 .
  6. Nikulainen, I, Salminen, AP, Seikkula, H, Högerman, M, Perez, IM, Koskinen, I et al.. Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland. Acta Oncol. 2023;62 (8):829-835. doi: 10.1080/0284186X.2023.2228446. PubMed PMID:37377029 .
  7. Valli, J, Haapiainen, H, Murtola, TJ, Huhtala, H, Kaipia, A, Raitanen, M et al.. Visual Analogue Scale and Expanded Prostate Cancer Index Composite-26 in the Evaluation of Urinary Continence Recovery After Three-Dimensional Laparoscopic Radical Prostatectomy, a Single-Center Prospective Registered Study. Urology. 2023;177 :103-108. doi: 10.1016/j.urology.2023.04.021. PubMed PMID:37146729 .
  8. Sattari, M, Kohvakka, A, Moradi, E, Rauhala, H, Urhonen, H, Isaacs, WB et al.. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. Endocr Relat Cancer. 2023;30 (8):. doi: 10.1530/ERC-22-0247. PubMed PMID:37140987 PubMed Central PMC10326635.
  9. Nätkin, R, Pennanen, P, Syvälä, H, Bläuer, M, Kesseli, J, Tammela, TLJ et al.. Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation. PLoS One. 2023;18 (2):e0281645. doi: 10.1371/journal.pone.0281645. PubMed PMID:36809527 PubMed Central PMC9942993.
  10. Joentausta, RM, Siltari, A, Rannikko, A, Murtola, TJ. Incidence of erectile dysfunction treatment after radical prostatectomy by Statin use in Finnish Nationwide Cohort Study. Scand J Urol. 2023;57 (1-6):53-59. doi: 10.1080/21681805.2023.2168746. PubMed PMID:36683437 .
  11. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023;83 (3):246-258. doi: 10.1002/pros.24456. PubMed PMID:36325820 .
  12. Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .

Search PubMed

2022
  1. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023;83 (3):246-258. doi: 10.1002/pros.24456. PubMed PMID:36325820 .
  2. Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .
  3. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2022; :. doi: 10.1038/s41391-022-00597-4. PubMed PMID:36131010 .
  4. Siltari, A, Syvälä, H, Lou, YR, Gao, Y, Murtola, TJ. Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor’s Immune Environment. Cancers (Basel). 2022;14 (17):. doi: 10.3390/cancers14174293. PubMed PMID:36077824 PubMed Central PMC9454444.
  5. Latvala, L, Tiihonen, M, Murtola, TJ, Hartikainen, S, Tolppanen, AM. Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer’s disease. Pharmacoepidemiol Drug Saf. 2022;31 (10):1110-1120. doi: 10.1002/pds.5503. PubMed PMID:35751619 PubMed Central PMC9542191.
  6. Peltomaa, AI, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers (Basel). 2022;14 (12):. doi: 10.3390/cancers14122920. PubMed PMID:35740586 PubMed Central PMC9221017.
  7. Salminen, JK, Mehtola, A, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2022;127 (4):704-711. doi: 10.1038/s41416-022-01817-3. PubMed PMID:35505251 PubMed Central PMC9381528.
  8. Siltari, A, Riikonen, J, Koskimäki, J, Pakarainen, T, Ettala, O, Boström, P et al.. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open. 2022;12 (4):e050264. doi: 10.1136/bmjopen-2021-050264. PubMed PMID:35487730 PubMed Central PMC9058683.
  9. Ahtinen, M, Vironen, J, Murtola, TJ. The risk of inguinal hernia repair after radical prostatectomy – a population-based cohort study. Scand J Urol. 2022;56 (3):191-196. doi: 10.1080/21681805.2022.2065357. PubMed PMID:35451920 .
  10. Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
  11. Salminen, JK, Murtola, TJ. Reply to: Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2022;150 (7):1214. doi: 10.1002/ijc.33887. PubMed PMID:34854487 .
  12. Vettenranta, A, Murtola, TJ, Raitanen, J, Raittinen, P, Talala, K, Taari, K et al.. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2022;8 (1):61-68. doi: 10.1001/jamaoncol.2021.5672. PubMed PMID:34817559 PubMed Central PMC8777566.

Search PubMed

2021
  1. Joentausta, RM, Rannikko, A, Murtola, TJ. Prostate Cancer-specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users. Eur Urol Open Sci. 2021;34 :86-93. doi: 10.1016/j.euros.2021.10.002. PubMed PMID:34934970 PubMed Central PMC8655383.
  2. Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
  3. Salminen, JK, Murtola, TJ. Reply to: Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2022;150 (7):1214. doi: 10.1002/ijc.33887. PubMed PMID:34854487 .
  4. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
  5. Enwald, M, Lehtimäki, T, Mishra, PP, Mononen, N, Murtola, TJ, Raitoharju, E et al.. Human Prostate Tissue MicroRNAs and Their Predicted Target Pathways Linked to Prostate Cancer Risk Factors. Cancers (Basel). 2021;13 (14):. doi: 10.3390/cancers13143537. PubMed PMID:34298752 PubMed Central PMC8307951.
  6. Murtola, TJ, Siltari, A. Statins for Prostate Cancer: When and How Much?. Clin Cancer Res. 2021;27 (18):4947-4949. doi: 10.1158/1078-0432.CCR-21-1891. PubMed PMID:34281913 .
  7. Raittinen, PVH, Syvälä, H, Tammela, TLJ, Häkkinen, MR, Ilmonen, P, Auriola, S et al.. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine. 2021;68 :103432. doi: 10.1016/j.ebiom.2021.103432. PubMed PMID:34144486 PubMed Central PMC8219992.
  8. Santala, EEE, Artama, M, Pukkala, E, Visvanathan, K, Staff, S, Murtola, TJ et al.. Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study. Cancers (Basel). 2021;13 (9):. doi: 10.3390/cancers13092087. PubMed PMID:33925829 PubMed Central PMC8123393.
  9. Vettenranta, A, Murtola, TJ, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of prostate cancer screening among men using antidiabetic medication. Sci Rep. 2021;11 (1):7363. doi: 10.1038/s41598-021-86534-2. PubMed PMID:33795720 PubMed Central PMC8016840.
  10. Haapiainen, H, Murtola, TJ, Raitanen, M. 3D laparoscopic prostatectomy: A prospective single-surgeon learning curve in the first 200 cases with oncologic and functional results. Scand J Urol. 2021;55 (3):242-248. doi: 10.1080/21681805.2021.1898465. PubMed PMID:33792488 .
  11. Peltomaa, AI, Raittinen, P, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. Prostate Cancer Prostatic Dis. 2021;24 (3):917-924. doi: 10.1038/s41391-021-00351-2. PubMed PMID:33790420 PubMed Central PMC8384625.
  12. Vihervuori, VJ, Talala, K, Taari, K, Lahtela, J, Tammela, TLJ, Auvinen, A et al.. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30 (5):982-989. doi: 10.1158/1055-9965.EPI-19-0580. PubMed PMID:33653815 .
  13. Salminen, JK, Kuoppamäki, V, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2021;149 (2):307-315. doi: 10.1002/ijc.33535. PubMed PMID:33634851 .
  14. Siltari, A, Auvinen, A, Murtola, TJ. Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040696. PubMed PMID:33572236 PubMed Central PMC7914977.
  15. Siltari, A, Riikonen, J, Murtola, TJ. Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function – A Randomized Clinical Trial. J Sex Med. 2021;18 (2):327-338. doi: 10.1016/j.jsxm.2020.11.003. PubMed PMID:33358241 .

Search PubMed

2020
  1. Siltari, A, Riikonen, J, Murtola, TJ. Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function – A Randomized Clinical Trial. J Sex Med. 2021;18 (2):327-338. doi: 10.1016/j.jsxm.2020.11.003. PubMed PMID:33358241 .
  2. Santala, EEE, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland. Cancer Epidemiol Biomarkers Prev. 2020;29 (11):2376-2382. doi: 10.1158/1055-9965.EPI-20-0711. PubMed PMID:32917663 .
  3. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
  4. Riikonen, J, Pakarainen, T, Siltari, A, Pienimäki, JP, Koskimäki, J, Murtola, TJ et al.. Urine colour as an indicator for anastomotic leakage after robot-assisted radical prostatectomy. Scand J Urol. 2020;54 (3):201-207. doi: 10.1080/21681805.2020.1750474. PubMed PMID:32308088 .
  5. Kinnunen, PT, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020;29 (1):208-215. doi: 10.1158/1055-9965.EPI-19-0147. PubMed PMID:31653681 .
  6. Santala, EEE, Rannikko, A, Murtola, TJ. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. Int J Cancer. 2020;146 (4):1175. doi: 10.1002/ijc.32745. PubMed PMID:31633796 .

Search PubMed

 

Tuni research portal

Research output